Dec. 24 at 1:39 PM
$AGEN 🔍 How strong is this report, really?
⭐ What makes it impressive
Heavily pretreated, immunotherapy‑resistant population:
Getting any responses in this group is difficult. A 23% overall response rate is meaningfully above what’s typically seen in refractory ovarian cancer, where response rates to late‑line therapies often fall below 10%.
Durable benefit:
A median duration of response of 9.7 months is notable for a population with few remaining options.
Median overall survival of 14.8 months:
For treatment‑refractory ovarian cancer, this is a strong signal. Many late‑line patients have median OS closer to 9–12 months depending on prior therapies.
Pan‑tumor activity:
The fact that BOT+BAL showed activity across multiple refractory solid tumors (per the broader C‑800‑01 dataset) suggests the mechanism may have broader relevance, not just a one‑off result.
